Why Reid Hoffman Left Microsoft’s Board to Focus on AI Cancer Drug Discovery

Reid Hoffman, the billionaire co-founder of LinkedIn, is stepping down from Microsoft’s board of directors to go all-in on a new venture: using artificial intelligence to discover cancer drugs. Microsoft disclosed the move in a June 2 SEC filing, noting that Hoffman informed the company he would not seek re-election at the 2026 shareholder meeting. The filing explicitly states there was no disagreement with Microsoft’s management, policies, or practices. The departure is amicable, but the reason behind it is telling.

Hoffman wants to return to “founder mode.” He told Microsoft CEO Satya Nadella on his Possible podcast that progress at Manus, the AI-powered drug discovery startup he co-chairs, has accelerated faster than expected. “I need to get back to founder mode,” he said. The podcast dropped the same day as the filing, underscoring the speed of events.

Manus, also known as Manas AI, launched in early 2025. Hoffman teamed with Siddhartha Mukherjee, the Pulitzer Prize-winning oncologist and author of The Emperor of All Maladies. The startup uses AI models to design novel molecules, then validates them in wet labs. Its initial targets include breast cancer, prostate cancer, and lymphoma. The company raised $24.6 million in seed capital from Hoffman, General Catalyst, and Greylock, later surpassing $50 million in total funding. Manus deliberately uses Microsoft’s Azure cloud and AI tools, a connection that now feels both convenient and constraining.

Hoffman sees a parallel to “Move 37,” the surprising move AlphaGo made against a human champion in 2016. In chemistry, that moment would mean AI generating compounds beyond human intuition. Cancer drug discovery could accelerate dramatically if the models deliver. Biotech has long suffered from high failure rates and decade-long timelines. AI promises to shrink both. Yet skepticism persists. Many AI drug startups have raised hundreds of millions with limited clinical proof. Manus has taken a measured path so far.

Hoffman’s exit removes a potential conflict of interest for Microsoft, as investors and regulators scrutinize overlaps between directors’ personal investments and corporate strategy. But it also removes a director steeped in Silicon Valley’s AI inner circle. Hoffman was an early investor in OpenAI, helped shape Microsoft’s initial $1 billion commitment in 2019, and sat on OpenAI’s board until early 2023. He also co-founded Inflection AI, which Microsoft later acquired for $650 million in an acqui-hire deal.

Industry observers note the move fits a pattern. Talented operators who advise big tech often feel the tug of their own ideas once technology reaches an inflection point. Hoffman has talked openly about agents, superagency, and AI’s effect on work. His new focus turns those concepts toward one of humanity’s hardest problems.

For Microsoft, the transition looks orderly. The board will likely add new voices with fresh AI or biotech perspectives. And Hoffman’s relationships in the startup world remain valuable even without a director title. But the news carries symbolic force. One of the most connected figures in tech has chosen a laboratory over the boardroom. He sees greater leverage in molecules than in minutes of governance meetings. That choice says as much about the state of AI as it does about Hoffman’s personal calculus.